RxDoctor Payments Data

Venkat Vavilala, MD

Nephrology · Merrillville, INNPI 1730186081

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.9% of the total across 313 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations.

$8,078in general payments, 2019–2025

Across 313 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$951
  • Vifor Pharma, Inc.$765
  • Fresenius USA Marketing, Inc.$692
  • AstraZeneca$688
  • Boehringer Ingelheim$489
  • ANI Pharmaceuticals, Inc.$447
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$7,74996%
  • Education$3294%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,078 in reported general payments places this provider in the 85th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana

Medicare billing

Part B allowed, 2024
$409,683
Medicare patients
760
Services billed
3,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide22$74,623
JardianceEmpagliflozin55$70,375
FarxigaDapagliflozin Propanediol36$46,740
LokelmaSodium Zirconium Cyclosilicate13$12,159
Sevelamer Carbonate44$8,295
Potassium Citrate ErPotassium Citrate34$3,289
Febuxostat14$2,191
Calcitriol44$818
Bumetanide16$767
Torsemide29$636
Hydralazine Hcl28$532
Valsartan28$530
Furosemide82$503
Chlorthalidone24$473
Amlodipine Besylate62$403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$692$74,62322 claims
Boehringer IngelheimJardiance$489$70,37555 claims
AstraZenecaFarxiga, Lokelma$688$58,89949 claims
ANI Pharmaceuticals, Inc.Valsartan$447$53028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 238 nephrology providers in Indiana.

Other nephrology in Merrillville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →